Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis

類似資料

• Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis
  著者:: CHOI, In Ah, 等
  出版事項: (2018)
• Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients
  著者:: Lee, Sang Jin, 等
  出版事項: (2015)
• Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients
  著者:: Sang Jin Lee, 等
  出版事項: (2015-01-01)
• Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
  著者:: Lee, Sang Jin, 等
  出版事項: (2017)
• Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea
  著者:: Song, Jason Jungsik, 等
  出版事項: (2018)